Alpha Tau Medical Ltd. (DRTS) — AI News Sentiment & Analysis

FDA clearance to complete enrollment and add sites for the pivotal REGAIN trial in recurrent glioblastoma, driven by positive interim safety and efficacy data. (Timing: Immediate (enrollment to recommence immediately), with trial completion likely within the next 12-18 months.)

Completion of patient enrollment in the pivotal ReSTART trial for Alpha DaRT® in recurrent cSCC. (Timing: Data maturation and FDA PMA submission process expected over the next 12-24 months.)

Positive updated clinical trial results (100% disease control, favorable safety) for Alpha DaRT in pancreatic cancer, presented at DDW 2026. (Timing: Near-term (as these are reported results), with follow-on catalysts expected with further trial advancements (e.g., Phase 2/3 initiation/results).)

FDA approval of an Investigational Device Exemption (IDE) supplement to expand the Alpha DaRT® IMPACT trial for pancreatic cancer, allowing more patients and a new combination therapy regimen. (Timing: The trial expansion is effective immediately, with recruitment for additional patients expected to finish in Q3 2026. Clinical progress will unfold over the medium term.)

The immediate catalysts include the recent Japanese marketing approval for head and neck cancer, positive pancreatic cancer trial data presented at ASCO, FDA approvals for new trials, and submission of the first module for PMA in skin cancer. Upcoming milestones include completion of patient recruitment in pivotal U.S. trials in Q1/Q2 2026. (Timing: Immediate impact from recent announcements; further catalysts expected within Q1 and Q2 2026.)